Literature DB >> 3511389

Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors.

D R Bertolini, G E Nedwin, T S Bringman, D D Smith, G R Mundy.   

Abstract

When leukocytes are exposed to mitogens or antigens in vitro, they release bone-resorbing activity into the culture supernatants which can be detected by bioassay. Like many lymphocyte-monocyte products, this activity has been difficult to purify because of its low abundance in activated leukocyte cultures and the unwieldy bioassay required to detect biological activity. Partially purified preparations of this activity inhibit bone collagen synthesis in organ cultures of fetal rat calvariae. Recent data suggest that both activated lymphocytes and monocytes release factors which could contribute to this activity. Recently, monocyte-derived tumour necrosis factor alpha (TNF-alpha) and lymphocyte-derived tumour necrosis factor beta (TNF-beta) (previously called lymphotoxin), two multifunctional cytokines which have similar cytotoxic effects on neoplastic cell lines, have been purified to homogeneity and their complementary DNAs cloned and expressed in Escherichia coli. As both of these cytokines are likely to be present in activated leukocyte supernatants, we tested purified recombinant preparations for their effects on bone resorption and bone collagen synthesis in vitro, and report here that both cytokines at 10(-7) to 10(-9) M caused osteoclastic bone resorption and inhibited bone collagen synthesis. These data suggest that at least part of the bone-resorbing activity present in activated leukocyte culture supernatants may be due to these cytokines.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3511389     DOI: 10.1038/319516a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  283 in total

Review 1.  Cartilage destruction and bone erosion in arthritis: the role of tumour necrosis factor alpha.

Authors:  R O Williams; M Feldmann; R N Maini
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

2.  Interactions between immune and bone cells: new insights with many remaining questions.

Authors:  J Lorenzo
Journal:  J Clin Invest       Date:  2000-09       Impact factor: 14.808

Review 3.  Metabolic bone disease in IBD.

Authors:  I Lopez; A L Buchman
Journal:  Curr Gastroenterol Rep       Date:  2000-08

Review 4.  Adalimumab (a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials.

Authors:  R Rau
Journal:  Ann Rheum Dis       Date:  2002-11       Impact factor: 19.103

5.  Adjunctive Nd:YAG laser application in chronic periodontitis: clinical, immunological, and microbiological aspects.

Authors:  Clara Gómez; Arantza Domínguez; Ana Isabel García-Kass; Juan Antonio García-Nuñez
Journal:  Lasers Med Sci       Date:  2010-06-10       Impact factor: 3.161

6.  Osteoporosis and gastrointestinal disease.

Authors:  Seymour Katz; Stuart Weinerman
Journal:  Gastroenterol Hepatol (N Y)       Date:  2010-08

7.  TNFalpha therapy in psoriatic arthritis and psoriasis.

Authors:  P Mease
Journal:  Ann Rheum Dis       Date:  2004-07       Impact factor: 19.103

8.  Tumour necrosis factor in synovial exudates.

Authors:  F S Di Giovine; G Nuki; G W Duff
Journal:  Ann Rheum Dis       Date:  1988-09       Impact factor: 19.103

9.  Production of an interleukin-1 inhibitor by cell line P388D1 murine macrophages stimulated with Haemophilus actinomycetemcomitans lipopolysaccharide.

Authors:  T Nishihara; T Koga; S Hamada
Journal:  Infect Immun       Date:  1988-11       Impact factor: 3.441

10.  Presence of tumour necrosis factor or a related factor in human basophil/mast cells.

Authors:  M Steffen; M Abboud; G K Potter; Y P Yung; M A Moore
Journal:  Immunology       Date:  1989-03       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.